Literature DB >> 8729749

Fungal infections in neutropenic patients. A 8-year prospective study.

M Nucci1, W Pulcheri, N Spector, A P Bueno, P C Bacha, M J Caiuby, A Derossi, R Costa, J C Morais, H P de Oliveira.   

Abstract

In this paper we report a eight-year prospective study designed to further characterize incidence, epidemiology, specific syndromes, treatment and prognosis associated with fungal infections in neutropenic patients. During the study period 30 fungal infections were diagnosed in 30 patients among 313 episodes of fever and neutropenia (10%). There were 15 cases of candidiasis, 5 pulmonary aspergillosis, 3 sinusitis by Aspergillus fumigatus, 5 infections by Fusarium sp., one infection by Trichosporon sp., and one infection due to Rhodotorula rubra. Blood cultures were positive in 18 cases (60%). The predisposing factors for fungal infection in multivariate analysis were the presence of central venous catheter (p < 0.001), longer duration of profound (< 100/mm3) neutropenia (p < 0.001), the use of corticosteroids (p < 0.001), gram-positive bacteremia (p = 0.002) and younger age (p = 0.03). In multivariate analysis only recovery of the neutropenia (p < 0.001) was associated with good prognosis whereas the diagnosis of infection by Fusarium sp. (p = 0.006) was strongly associated with a poor outcome. The death rate was 43%. There was no statistically significant difference in the death rate between patients who did receive (52%) or did not receive (50%) antifungal treatment. Identifying patients at risk, specific syndromes and prognostic factors may help to reduce the high mortality associated with disseminated fungal infections in neutropenic patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8729749     DOI: 10.1590/s0036-46651995000500004

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  15 in total

Review 1.  Developments in fungal taxonomy.

Authors:  J Guarro; A M Stchigel
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

2.  The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.

Authors:  Brad J Spellberg; Ashraf S Ibrahim; Valentina Avenissian; Scott G Filler; Carter L Myers; Yue Fu; John E Edwards
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans.

Authors:  Shuichi Ito; Joao Pedras-Vasconcelos; Dennis M Klinman
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis.

Authors:  Ashraf S Ibrahim; Brad J Spellberg; Valentina Avanesian; Yue Fu; John E Edwards
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 5.  Hospital epidemiology and infection control in acute-care settings.

Authors:  Emily R M Sydnor; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

6.  Safety and efficacy of activated transfected killer cells for neutropenic fungal infections.

Authors:  Lin Lin; Ashraf S Ibrahim; Beverlie Baquir; Yue Fu; David Applebaum; Julie Schwartz; Amy Wang; Valentina Avanesian; Brad Spellberg
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

7.  Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.

Authors:  Ashraf S Ibrahim; Brad J Spellberg; Valentina Avenissian; Yue Fu; Scott G Filler; John E Edwards
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 8.  Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment.

Authors:  R Herbrecht; S Neuville; V Letscher-Bru; S Natarajan-Amé; O Lortholary
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

9.  The Pathophysiology and Treatment of Candida Sepsis.

Authors:  Brad Spellberg; John E. Edwards
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

10.  Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis.

Authors:  Brad Spellberg; Douglas Johnston; Quynh Trang Phan; John E Edwards; Samuel W French; Ashraf S Ibrahim; Scott G Filler
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.